3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Phase NA
1
Phase EARLY_PHASE1
1
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
141
Other hematologic neoplasm
109
Plasma cell
62
CNS
37
Sarcoma
27
Gynecologic
27
Thoracic
21
Gastrointestinal
19
Myeloid
18
Dermatologic
12
Head & Neck
11
Genitourinary
11
Breast
11
Endocrine
2
Classical hematology
2
Other solid neoplasm
1
NET
1
Conditions
Neuroendocrine Tumors
43
Carcinoma, Neuroendocrine
8
Gastro-enteropancreatic neuroendocrine tumor
7
Sarcoma
6
Carcinoid Tumor
6
Stomach Neoplasms
5
Small Cell Lung Carcinoma
5
Paraganglioma
5
Neoplasms
5
Prostatic Neoplasms
4
Pheochromocytoma
4
Neoplasm Metastasis
4
Lung Neoplasms
4
Colorectal Neoplasms
4
Carcinoma, Non-Small-Cell Lung
4
Carcinoma
4
Thyroid Neoplasms
3
Neuroblastoma
3
Carcinoma, Renal Cell
3
Thyroid Diseases
2
Thoracic Neoplasms
2
Respiratory Tract Neoplasms
2
Respiratory Tract Diseases
2
Ovarian Neoplasms
2
Neuroectodermal Tumors
2
Neoplasms, Germ Cell and Embryonal
2
Neoplasms by Site
2
Neoplasms by Histologic Type
2
Meningioma
2
Medulloblastoma
2
Interventions
olaparib
1
lutetium Lu 177 dotatate
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Recurrence
×
NET
×
Clear all
NCT06607692
2026-04-14
LUPARPED
Fundación de investigación HM
Phase 1/2
Recruiting
25 enrolled